<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>International Journal of Preventive Medicine (Int J Prev Med)</JournalTitle><Issn>2008-7802</Issn><Volume>10</Volume><Issue>10</Issue><PubDate PubStatus="epublish"><Year>2020</Year><Month>02</Month><Day>09</Day></PubDate></Journal><title locale="en_US">Inflammatory Bowel Disease Registry and Monitoring: Feasibility Study and Application (Isfahan Inflammatory Bowel Disease Surveillance Project)</title><FirstPage>2181</FirstPage><LastPage>2181</LastPage><Language>EN</Language><AuthorList><Author><affiliation locale="en_US">Gastrointestinal and Hepatobiliary Diseases Research Center, Poursina Hakim Research Institute for Health Care Development &amp; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences</affiliation></Author><Author><affiliation locale="en_US">Gastrointestinal and Hepatobiliary Diseases Research Center, Poursina Hakim Research Institute for Health Care Development &amp; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences</affiliation></Author><Author><affiliation locale="en_US">Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences</affiliation></Author><Author><affiliation locale="en_US">Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences</affiliation></Author><Author><affiliation locale="en_US">Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences</affiliation></Author><Author><affiliation locale="en_US">Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences</affiliation></Author><Author><affiliation locale="en_US">Gastrointestinal and Hepatobiliary Diseases Research Center, Poursina Hakim Research Institute for Health Care Development, Isfahan</affiliation></Author><Author><affiliation locale="en_US">Gastrointestinal and Hepatobiliary Diseases Research Center, Poursina Hakim Research Institute for Health Care Development, Isfahan</affiliation></Author></AuthorList><History><PubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>09</Day></PubDate></History><abstract locale="en_US">&lt;p&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Background&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;Inflammatory bowel disease (IBD) incidence has been increased in Iran as a developing&lt;br /&gt;country. Surveillance is a standard method for accessing valid data about disease epidemiology to&lt;br /&gt;make relevant decisions for disease control, prevention, and management. We designed Isfahan&lt;br /&gt;IBD Surveillance Project (IISP) to make a surveillance system in this area. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Methods&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;The project&lt;br /&gt;is designed in 3 phases. At the first phase, a model of step‑wise approach (core, expanded core, and&lt;br /&gt;optional variables) for IBD surveillance was designed and implemented among IBD patients registered&lt;br /&gt;at a major referral gastrointestinal diseases clinic in Isfahan. Data bank program and its software&lt;br /&gt;were designed with suitable and multifunctional features. A total of 352 IBD cases were registered to&lt;br /&gt;data bank and analyzed as a pilot study of IISP. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Results&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;A total of 352 IBD patients, including 245&lt;br /&gt;ulcerative colitis (UC), 80 Crohn’s disease (CD), and 27 indeterminate colitis, were registered to the&lt;br /&gt;data bank. Bloody stool and abdominal cramp were the most common presentation symptom among&lt;br /&gt;UC and CD, respectively. Extensive pancolitis was the most prevalent phenotype (40%) of UC. Over&lt;br /&gt;two‑thirds of our IBD patients were in remission states. Biologic agents had been prescribed in about&lt;br /&gt;10% of patients during disease. Primary sclerosing cholangitis was detected in about 7% and 10% of&lt;br /&gt;CD and UC patients, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span class="fontstyle0"&gt;&lt;strong&gt;Conclusions&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle2"&gt;Valid data from a standard surveillance system are&lt;br /&gt;a relevant, trustworthy tool for making decision by health policy‑makers. Integrated comprehensive&lt;br /&gt;interventional programs for disease control and management is the second phase of IISP.&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span class="fontstyle0" style="color: #00652e;"&gt;&lt;strong&gt;Keywords&lt;/strong&gt;: &lt;/span&gt;&lt;span class="fontstyle3"&gt;Colitis, Crohn’s disease, inflammatory bowel diseases, Iran, registries, ulcerative&lt;/span&gt;&lt;/p&gt;</abstract><web_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/2181</web_url><pdf_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/download/2181/717717977</pdf_url></Article></Articles>
